AUR-105 is under clinical development by Aurigene Discovery Technologies and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase I drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AUR-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AUR-105 overview

AUR-105 is under development for the treatment of solid tumor, non hodgkin lymphoma or hodgkin lymphoma. The drug candidate is administered through oral route. It acts by targeting leukocyte surface antigen CD47.

Aurigene Discovery Technologies overview

Aurigene Discovery Technologies (Aurigene), a subsidiary of Dr. Reddy’s Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns integrated drug discovery infrastructure from hit generation to pre-clinical development. Aurigene’s pipeline portfolio consists of products for immunoncology PD-L1 and Vista, TIM-3 and PD1, CD47; precision oncology products IRAK4, NAMPT, KRAS, CDK7; Epigenetics products BET Bromodomain, PRMT5, CBP and P300; and inflammatory product ROR Inverse Agonist. It operates through collaboration with mid-pharma companies. Aurigene is headquartered in Bangalore, Karnataka, India.

For a complete picture of AUR-105’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.